

ABSTRACT OF THE DISCLOSURE

Provided is a method for treating ocular neovascularization by delivering a vector, preferably a viral vector, to target cells in the eye of a subject. The vector contains a a
5 polynucleotide sequence encoding an angiostatic gene product, under the control of a promoter sequence. The angiostatic gene product is expressed in the target cells, thereby treating the ocular neovascularization in the subject.